Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Sells $317,250.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ADMA Biologics Price Performance

ADMA opened at $21.18 on Monday. The firm has a market cap of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64. The stock has a 50-day moving average price of $18.86 and a 200-day moving average price of $14.89. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the previous year, the company earned $0.01 earnings per share. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the second quarter worth $29,000. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics during the third quarter valued at $30,000. EntryPoint Capital LLC bought a new stake in ADMA Biologics in the 1st quarter worth about $31,000. Larson Financial Group LLC purchased a new position in ADMA Biologics in the 3rd quarter worth about $31,000. Finally, National Bank of Canada FI purchased a new position in ADMA Biologics in the 3rd quarter worth about $35,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.